Q2 EPS Estimates for Upstream Bio Decreased by William Blair

Upstream Bio, Inc. (NASDAQ:UPB - Free Report) - Research analysts at William Blair cut their Q2 2025 earnings per share (EPS) estimates for shares of Upstream Bio in a research report issued to clients and investors on Tuesday, May 6th. William Blair analyst M. Phipps now forecasts that the company will post earnings of ($0.59) per share for the quarter, down from their prior estimate of ($0.42). The consensus estimate for Upstream Bio's current full-year earnings is ($4.30) per share. William Blair also issued estimates for Upstream Bio's Q3 2025 earnings at ($0.70) EPS, Q4 2025 earnings at ($0.80) EPS, FY2025 earnings at ($2.61) EPS, Q1 2026 earnings at ($0.81) EPS, Q2 2026 earnings at ($0.82) EPS, Q3 2026 earnings at ($0.73) EPS, Q4 2026 earnings at ($0.57) EPS, FY2026 earnings at ($2.89) EPS, FY2027 earnings at ($2.35) EPS, FY2028 earnings at ($2.45) EPS and FY2029 earnings at ($2.62) EPS.

Upstream Bio Trading Up 4.5 %

Shares of UPB opened at $8.58 on Thursday. Upstream Bio has a 52 week low of $5.14 and a 52 week high of $29.46. The firm's 50-day simple moving average is $8.00 and its 200 day simple moving average is $13.81.

Upstream Bio (NASDAQ:UPB - Get Free Report) last released its quarterly earnings data on Tuesday, May 6th. The company reported ($0.51) EPS for the quarter, missing analysts' consensus estimates of ($0.49) by ($0.02). The business had revenue of $0.57 million for the quarter, compared to analysts' expectations of $0.71 million.

Hedge Funds Weigh In On Upstream Bio

Several institutional investors and hedge funds have recently made changes to their positions in the company. FMR LLC acquired a new stake in shares of Upstream Bio during the fourth quarter worth $117,977,000. Orbimed Advisors LLC bought a new stake in Upstream Bio in the 4th quarter valued at about $93,603,000. Decheng Capital LLC acquired a new position in shares of Upstream Bio during the 4th quarter worth approximately $54,010,000. TCG Crossover Management LLC bought a new position in shares of Upstream Bio during the fourth quarter worth approximately $44,856,000. Finally, Enavate Sciences GP LLC acquired a new stake in shares of Upstream Bio in the fourth quarter valued at approximately $40,438,000.

Upstream Bio Company Profile

Upstream Bio, Inc, a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.